Morphoceuticals, a Boston, MA-based biotechnology company advancing artificial intelligence-guided electroceuticals to regenerate limbs, repair tissues, and regenerate organs, raised $8M in Seed-2 funding.
The round was led by Prime Movers Lab and initial investor Juvenescence.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Michael Hufford, Ph.D., Morphoceuticals is pioneering the use of artificial intelligence-guided electroceuticals to regenerate limbs, repair tissues, and regenerate organs, leveraging the work of Professors Michael Levin and David Kaplan from Tufts University. Using proprietary combinations of ion channel and gap junction modulators, the company focuses on inducing limb regeneration, improving amputation stump health, promoting organ regeneration, and the treatment of channelopathies.
FinSMEs
15/02/2023